Quantum Technology Partners

Magnolia Broadband is a fabless semiconductor company within the wireless communications industry who has invented and patented Mobile Transmit Diversity (MTD), a beam forming technology which allows wireless network operators to offer higher data throughput and improve coverage with no change in base stations or infrastructure standards. MTD can be deployed as a chip or as a software-only solution. Magnolia has industry's broadest IP portfolio: 28 issued patents and 24 patents pending in US, 2 issued patents and 12 pending (International/ 10 countries). issued patents are broad, fundamental & key with technical and commercial essential claims essential to MTD. Some of Magnolia's patents have broad implications beyond MTD. Magnolia increases spectrum utilization (network capacity) by 40%, coverage and extended performance (QoS) for voice & data services offering a field proven 4 dB gain in uplink; extends battery life and SAR emissions; Rapid and cost effective deployment- NO modifications to wireless standards and legacy cellular network. Magnolia's MTD supports multi-band standards and protocols.

Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.

Corium International is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development.

StrataGent Life Sciences, Inc. is a specialty drug therapy company developing painless, non-invasive versions of therapies that would otherwise be injected. Its products are based on its proprietary microjet technology, which delivers large and small therapeutic molecules without a device penetrating into or through the skin. In May of 2004, StrataGent received a $2 million award from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology to support the development of the StrataGent microjet technology.

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

IMI Intelligent Medical Implants develops and markets intelligent retinal implant systems for degenerative retinal disorders. The company offers The Intelligent Retinal Implant System, an adaptive visual prosthesis that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration. IMI Intelligent Medical Implants was founded in 2002 and is based in Zug, Switzerland.

Magnolia Broadband is a fabless semiconductor company within the wireless communications industry who has invented and patented Mobile Transmit Diversity (MTD), a beam forming technology which allows wireless network operators to offer higher data throughput and improve coverage with no change in base stations or infrastructure standards. MTD can be deployed as a chip or as a software-only solution. Magnolia has industry's broadest IP portfolio: 28 issued patents and 24 patents pending in US, 2 issued patents and 12 pending (International/ 10 countries). issued patents are broad, fundamental & key with technical and commercial essential claims essential to MTD. Some of Magnolia's patents have broad implications beyond MTD. Magnolia increases spectrum utilization (network capacity) by 40%, coverage and extended performance (QoS) for voice & data services offering a field proven 4 dB gain in uplink; extends battery life and SAR emissions; Rapid and cost effective deployment- NO modifications to wireless standards and legacy cellular network. Magnolia's MTD supports multi-band standards and protocols.

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.